Evidence map›Paper›PMID 35713775›Full record

ReviewCurrent neurology and neuroscience reports2022

Moving the Dial Toward Equity in Parkinson's Disease Clinical Research: a Review of Current Literature and Future Directions in Diversifying PD Clinical Trial Participation.

Jennifer Adrissi, Jori Fleisher

Abstract readReview
In one paragraph

Review in Current neurology and neuroscience reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Specific Medication Literacy in Older Adults with Asthma.The journal for nurse practitioners : JNP · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jennifer AdrissiDepartment of Neurology, Northwestern University Feinberg School of Medicine, 710 N. Lake Shore Dr, 11th Floor, Chicago, IL, 60611, USA. jennifer.adrissi@northwestern.edu.ORCID 0000-0003-4400-7442
Jori FleisherDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.ORCID 0000-0001-5003-9091

Funding

Reaching the Most Vulnerable: A Novel Model of Care in Advanced Parkinson's DiseaseK23NS097615 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI FLEISHER, JORI ERIN · 2017 to 2021
$921k
NINDS NIH HHS K23 NS097615
6 · The paper itself

Abstract

purpose of reviewParkinson's disease (PD), the second most common neurodegenerative disease, has a worldwide prevalence projected at 12 million by 2040. While PD has been extensively researched, our understanding of the disease is based on research studies that include mostly participants of European descent. The lack of diversity in clinical trial enrollment has limited the generalizability of scientific discoveries in the field. Here, we discuss contributors to racial and ethnic disparities in PD clinical research enrollment, summarize recently proposed and tested interventions, and propose next steps to increase equity and representation in PD research. RECENT

findingsEnrollment in PD clinical research is vulnerable to upstream disparities and inequities from PD awareness to access to specialized PD centers. While additional research is still needed, recent studies have identified some potential strategies for increasing underrepresented minority (URM) recruitment including increasing the availability of linguistically and culturally diverse research materials and team members, partnering with community organizations, and forming relationships with URM-serving community physicians. To move the dial toward equity in PD research, it will be necessary to implement known successful strategies and further investigate additional contributors to the underrepresentation of URMs in PD clinical research while developing and testing interventions to address these factors.

Indexed as

Parkinson DiseasePatient ParticipationClinical Trials as TopicCultural DiversityEthnicityHumansMinority GroupsClinical trialsDiversityEquityParkinson’s diseaseResearch

Identifiers

PMID35713775
PMCPMC9578442

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.